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Study Objective: Long-term use of nonsteroidal anti-inflammatory drugs, including selective and nonselective
cyclooxygenase inhibitors, has been suggested to be associated with cardiovascular (CV) safety risks. Data are
limited regarding CV risks associated with short-term nonsteroidal anti-inflammatory drug use, including
injectable formulations, although it has been suggested that even a single dose may increase CV adverse event
(AE) risk. The objective of this study was to examine the CV safety of an injectable diclofenac formulation
solubilized with hydroxypropyl-β-cyclodextrin (HPβCD) when given for ≤5 days postoperatively.
Design:A pooled analysis of CVAEs from 2 pivotal phase III clinical trials examining the efficacy and safety of
intravenous (IV) HPβCD-diclofenac vs placebo and the active comparator ketorolac was conducted.
Setting: Postoperative, with treatment initiated in the postanesthesia care unit ≤6 hours postsurgery.
Patients: Overall, 608 abdominal/pelvic and orthopedic surgery patients met inclusion criteria and received ≥1
study medication dose.
Interventions: Patients received either HPβCD-diclofenac, ketorolac, or placebo via IV bolus injection every
6 hours, for ≤5 days postsurgery.
Measurements:CVAEs, reported by study investigators,were evaluated through the treatment period and follow-
up (≤37 days after last study medication dose), and relative CV AE risks were estimated.
Main Results: IVHPβCD-diclofenac was not associated with increased treatment-emergent CVAE incidence vs
placebo (11.6% vs 12.2%; relative risk, 0.96 [95% confidence interval, 0.56-1.62]). Serious CV AEs as well as
treatment-related AEs were uncommon, and there were no reports of myocardial infarction or cerebrovascular
accident. CV AEs were uncommon during the follow-up period, occurring in 1.3%, 0%, and 1.4% of patients in
the HPβCD-diclofenac, ketorolac, and placebo groups, respectively.
Conclusions: Although a longer duration follow-up study in a larger patient population would expand our
understanding of potential CV risks, the present analysis suggests that postoperative use of HPβCD-diclofenac
does not present an added CV safety risk over placebo.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) have
long been used to manage postoperative pain both alone and
in combination with opioid analgesics [1]. When used as part
of a multimodal analgesia regimen, NSAIDs may limit the
requirement for opioids and, therefore, help to reduce the
incidence of common opioid-related adverse events such as
nausea and vomiting that can slow recovery from surgery [2].
Although NSAIDs are typically used to manage acute
mild-to-moderate pain, general safety concerns related to this
drug class include potential risks of bleeding and renal
complications [3]. These concerns can limit NSAID use,
particularly in at-risk patients, such as the elderly or patients
with preexisting renal insufficiency [4]. In addition,
cardiovascular (CV) risks can be of concern with NSAID
use, and caution is advised when prescribing NSAIDs to
patients with established CV risks, including older patients
or those with a history of CV disease [4,5]. Because of
concerns about CV risks, NSAID manufacturers in the
United States are required to include warnings about
potential CV risks in all product labeling [6].
Recent observational studies and meta-analyses have
identified CV safety risks associated with prolonged or
chronic use of NSAIDs, including selective cyclooxygenase
(COX) inhibitors and nonselective NSAIDs such as
diclofenac [7-13], which may contribute to concernsamong clinicians prescribing NSAIDs for long-term use.
On the other hand, data are limited with respect to potential
CV risks associated with short-term NSAID use, as would be
common with an injectable NSAID given for acute
postoperative pain management. Furthermore, it is not
clear, based on the current evidence regarding long-term or
chronic NSAID use such as in populations with arthritis,
what the threshold for increased CV risk is in terms of
duration of exposure in a population treated for acute
postoperative pain.
Hydroxypropyl-β-cyclodextrin (HPβCD)–diclofenac is a
novel formulation of the NSAID diclofenac, in which the
diclofenac molecule is solubilized with HPβCD. This allows
diclofenac to be administered as a low-volume intravenous
(IV) bolus. When administered as a single dose, HPβCD-
diclofenac has been associated with rapid analgesia and a
lower incidence of thrombophlebitis when compared to an
IV diclofenac formulation solubilized with polyethylene
glycol and benzyl alcohol [14,15]. The overall efficacy and
safety of repeated-dose HPβCD-diclofenac in postsurgical
populations have been established in a series of clinical trials
[16-18]. This includes evidence demonstrating HPβCD-
diclofenac's efficacy in the treatment of moderate-to-severe
acute pain without the need for additional agents, such as
opioids [16,17]. In line with single-dose study data, a safety
study in 971 surgical patients receiving repeated-dose
HPβCD-diclofenac demonstrated treatment-related infusion
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in 3.4%, 0.2%, and 0.2% of patients, respectively [18].
Given the importance of understanding the CV risks
associated with the use of any NSAID, the objective of the
current study was to examine the incidence of CV adverse
events (AEs) in patients receiving IV HPβCD-diclofenac for
the management of acute postoperative pain. This examina-
tion of CV safety consisted of an analysis of pooled data
from 2 randomized, double-blind, placebo- and active
comparator–controlled phase III HPβCD-diclofenac effica-
cy trials in which patients received HPβCD-diclofenac for
≤ 5 days after an abdominal/pelvic or orthopedic
procedure [16,17].2. Materials and methods
Both trials included in the pooled analysis were registered
with clinicaltrials.gov (trial identifiers NCT00448110 and
NCT 00507026). After institutional review board approval,
all patients provided institutional review board–approved
written informed consent. For detailed study methods, see
Gan et al [16] and Daniels et al [17].
2.1. Patients
Patients were screened for study inclusion if they were
scheduled to undergo abdominal/pelvic or orthopedic
surgery within 2 (abdominal/pelvic procedures) or 3
(orthopedic procedures) weeks and were expected to require
IV analgesia for the management of moderate to severe
postoperative pain (Supplementary Table 1). Key patient
inclusion criteria for both studies were age ≥18 years at
screening and moderate to severe pain within 6 hours after
surgery, defined as pain intensity ≥50 mm on a 0- to
100-mm visual analog scale. The upper age limit for study
inclusion was 65 years in the abdominal/pelvic surgery study
and 85 years in the orthopedic surgery study. Females of
childbearing age were required to have a negative pregnancy
test at screening as well as be practicing abstinence or using
an approved method of contraception. Patients were
excluded from either study if they had a history of
uncontrolled chronic disease that would contraindicate
study participation or recent history (≤6 months) of CV
events such as myocardial infarction (MI) or stroke; had a
known allergy to diclofenac, NSAIDs, morphine, anes-
thetics, or any of the excipients of the study preparation; had
a clinically significant laboratory or electrocardiographic
result at baseline or screening; or had taken monoamine
oxidase inhibitors, tryptophan, carbamazepine, or valproate
≤2 weeks before taking the study drug. Patients were also
excluded if they had taken aspirin (except for antiplatelet
cardiac protection), other NSAIDs, or other common
centrally or peripherally acting analgesic drugs, centrally
acting adjuvants, major and minor tranquilizers, or antihis-tamines ≤24 hours before study drug administration, with
the exception of medications administered during the
procedure. To further minimize potential effects due to
ongoing NSAID or COX-2 inhibitor use and in line with
practices to minimize surgical risk factors, long-acting
NSAIDs or COX-2 inhibitors (eg, naproxen, rofecoxib,
sustained-release analgesics) were to be discontinued at least
3 days before surgery. Heparin/low-molecular-weight heparin
(LMWH) and vitamin K antagonists (Coumadin/warfarin)
were permitted as concomitant medications.2.2. Study design and outcomes
Both studies included in the pooled analysis were
randomized, double-blind, multicenter, placebo- and active
comparator–controlled phase III studies. After meeting
inclusion criteria, patients in both studies were randomly
assigned to receive HPβCD-diclofenac, ketorolac trometha-
mine, or placebo according to a computer-generated random
number code. Clinical staff and patients were blinded to
treatment group assignment in both studies; however, dose
levels (see below) were not blinded in the orthopedic surgery
study. In the abdominal/pelvic surgery population, patients
received either 18.75 mg or 37.5 mg HPβCD-diclofenac,
30 mg ketorolac, or placebo. In the orthopedic surgery
population, patients in the HPβCD-diclofenac group re-
ceived a dosage of 18.75 mg, 37.5 mg, or 50 mg, based on
the presence of defined risk factors. The 18.75-mg dose was
given if patient weight was b50 kg, age was N65 years, or if
the patient had NSAID-related gastrointestinal risk factors,
hepatic impairment, or renal impairment (ie, high-risk
patients), whereas the upward-adjusted 50-mg dose was
given if patient weight was ≥95 kg and no predefined risk
factors were present. There was similar dose adjustment for
ketorolac in orthopedic surgery patients, with a standard dose
of 30 mg and a dose of 15 mg given to high-risk patients,
defined according to the same criteria used to define high risk
for patients receiving HPβCD-diclofenac.
Study medication was given as an IV bolus injection. The
first dose was given within the first 6 hours after surgery, and
subsequent doses were given every 6 hours until patient
discharge or withdrawal/discontinuation from the study. The
37.5-mg dose as well as adjusted doses based on risk factors/
patient weight were based on data from previous clinical and
pharmacokinetic studies [19,20]. Similarly, ketorolac dosage
was in line with label dosing and administration instructions,
which specify 30 mg every 6 hours (maximum 120 mg/d)
for patients b65 years old and 15 mg every 6 hours
(maximum 60 mg/d) for patients ≥65 years old, high-risk
patients, or patients b50 kg [21]. Abdominal/pelvic surgery
patients were observed for ≥48 hours after first study drug
dose and for up to 5 days. Orthopedic surgery patients were
observed for ≥24 hours after first dose and for up to 5 days.
Rescue medication (bolus IV morphine) was available to
patients upon request, up to once every 3 hours after the first
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adequate analgesia, the patient was withdrawn from the
study and given pain medication in accordance with the
investigator's usual practice.
2.3. Safety assessments
Safety was monitored by AEs, physical examination,
laboratory testing, vital sign testing, 12-lead electrocardiog-
raphy, and evaluation of injection site thrombophlebitis and
wound healing. AEs observed by the study investigators
were recorded from baseline through the 30-day follow-up
period after first administration of study drug in the
abdominal/pelvic surgery study and from screening through
the 30- to 37-day follow-up period after last administration of
study drug in the orthopedic surgery study. CV AEs were
coded in accordance with the Medical Dictionary for
Regulatory Activities preferred term and by system organ
class [22], and the observations reported herein likewise use
the Medical Dictionary for Regulatory Activities nomencla-
ture. AEs were graded using the National Cancer Institute
Common Terminology Criteria for AEs v.3.0 [23]. The
relationship of each AE to study treatment was classified by
the investigator as either “not related,” “unlikely,” “suspected,”
or “probable.”
2.4. Statistical analysis
For both studies included in this analysis, sample size was
based on calculated values defining the number of patients
required to detect a clinically significant difference in each
study's respective primary efficacy measure (see Gan et al
[16], Daniels et al [17]). Analyses of treatment-emergent CV
AEs (first occurring or worsening in severity during the
study period) were performed on the safety population for
both studies using SAS (Cary, NC) version 9.1 or later and
included analysis in the overall population as well as in
subgroups based on procedure type and age. Pooled CV AE
incidences were evaluated for all treatment groups and
relative risks (RRs) and 95% confidence intervals (CIs) of
CV AEs for active treatments vs placebo were calculated,
where appropriate. To further examine differences across treatment
groups, P values were calculated from analysis of variance for
numerical variables and Cochran-Mantel-Haenszel test for cate-
gorical variables. P b .05 was defined as statistically significant.3. Results
3.1. Demographics
The pooled safety population analyzed in this study
included a total of 608 patients who met inclusion criteria
and received ≥1 dose of HPβCD-diclofenac, ketorolac, or
placebo after abdominal/pelvic or orthopedic surgery. Thispopulation included 331 patients who underwent an
abdominal/pelvic procedure and 277 patients who underwent
an orthopedic procedure. The HPβCD-diclofenac, ketorolac,
and placebo treatment groups included 318, 142, and 148
patients, respectively. Overall, 88.4%, 88.0%, and 82.4% of
patients in the HPβCD-diclofenac, ketorolac, and placebo
groups, respectively, completed the study in which they were
enrolled. There were no significant differences in terms of
patient age, sex, weight, operative procedure, or receipt of
heparin/LMWH or Coumadin/warfarin across treatment
groups (Table 1). Across treatment groups, approximately
three-quarters of patients were female, most patients were
≤65 years old, and N75% of patients received study drug or
placebo for ≤2 days (≤8 doses).
3.2. CV safety: adverse events, severity,
relationship to treatment, and timing
Overall, ≥1 CV AE occurred in 11.6% (n = 37/318) of
patients in the HPβCD-diclofenac treatment group, 10.6%
(n = 15/142) of patients in the ketorolac group, and 12.2%
(n = 18/148) of patients in the placebo group (Table 2). The
risk of experiencing a CV AE was not significantly different
in patients receiving HPβCD-diclofenac vs placebo (RR,
0.96 [0.56-1.62]; P = .83), and the same was true for
treatment with ketorolac (0.87 [0.46-1.66]; P = .55). The
most common CV AEs were hypotension (n = 22 patients
overall, 3.6%), thrombophlebitis (16 patients, 2.6%),
tachycardia (16 patients, 2.6%), and hypertension (7 patients,
1.2%). Notably, there were no reports ofMI or cerebrovascular
accident (CVA) in any treatment group. There were 1
incidence of angina pectoris (in ketorolac group), 2 incidences
of congestive heart failure (1 each in the ketorolac and placebo
groups), and 3 incidences of deep vein thrombosis (all in
HPβCD-diclofenac group).
Cardiac events tended to occur less frequently in patients
receiving HPβCD-diclofenac (n = 8/318, 2.5%) vs
patients receiving either placebo (n = 7/148, 4.7%) or
ketorolac (n = 7/142, 4.9%) (Table 2). Vascular events
were more common than cardiac disorders in all 3 treatment
groups, occurring in 9.7% (n = 31/318) of patients receiving
HPβCD-diclofenac, 7.7% (n = 11/142) of patients receiving
ketorolac, and 9.5% (n = 14/148) of patients receiving
placebo. HPβCD-diclofenac was not associated with a
significant effect on AE risk vs placebo with respect to
either cardiac (RR, 0.53 [0.20-1.44]; P = .18) or vascular
(RR, 1.03 [0.57-1.88]; P = .94) events specifically.
There were no deaths resulting from CV AEs or any other
cause during the treatment or follow-up period. Serious CV
AEs (SAEs) occurred in 3 patients in the HPβCD-diclofenac
group (0.9%; all deep vein thrombosis; Table 3). There was 1
SAE each in the ketorolac (0.7%; cardiac failure congestive)
and placebo (0.7%; hypotension) treatment groups. Most CV
AEs were mild or moderate in severity, and treatment-related
CV AEs were uncommon across the study population,
occurring in 1.6% (n = 5/318), 0.7% (n = 1/142), and 1.4%
Table 1 Study population disposition and demographics (patients receiving ≥1 dose of study medication).
HPβCD-diclofenac (n = 318) a Ketorolac (n = 142) b Placebo (n = 148) P c
Completed 281 (88.4%) 125 (88.0%) 122 (82.4%) –
Withdrew d 37 (11.6%) 17 (12.0%) 26 (17.6%) –
Age (y), mean (SD) 48.9 (14.1) 48.0 (14.7) 48.6 (14.1) 0.81
Age group
18-50 y, n (%) 176 (55.3%) 79 (55.6%) 89 (60.1%) 0.70
N50-65 y, n (%) 102 (32.1%) 49 (34.5%) 41 (27.7%)
N65 y, n (%) 40 (12.6%) 14 (9.9%) 18 (12.2%)
Sex
Male, n (%) 85 (26.7%) 35 (24.6%) 41 (27.7%) 0.83
Female, n (%) 233 (73.3%) 107 (75.4%) 107 (72.3%)
Weight (kg), mean (SD) 86.0 (20.2) 85.5 (21.9) 84.8 (21.2) 0.83
Procedure type e
Abdominal/pelvic, n (%) 173 (54.4%) 82 (57.7%) 76 (51.4%) 0.55
Orthopedic, n (%) 145 (45.6%) 60 (42.3%) 72 (48.6%)
Doses received, mean (SD) 7.3 (3.4) 7.5 (3.5) 6.2 (3.7) –
1-6 doses, n (%) 101 (31.8%) 43 (30.3%) 71 (48.0%) –
7-8 doses, n (%) 150 (47.2%) 67 (47.2%) 53 (35.8%)
N8 doses, n (%) 67 (21.1%) 32 (22.5%) 24 (16.2%)
Total dose received, mg mean (SD) 226.7 (138.7) 206.6 (92.1) 0.0 (0.0) –
Concomitant anticoagulants f
Heparin/LMWH 53 (16.7%) 25 (17.6%) 33 (22.3%) 0.33
Enoxaparin 1 (0.3%) – 1 (0.7%)
Enoxaparin sodium – 2 (1.4%) –
Lovenox 44 (13.8%) 20 (14.1%) 26 (17.6%)
Heparin 7 (2.2%) 3 (2.1%) 6 (4.1%)
Heparin sodium 1 (0.3%) – –
Vitamin K antagonists 13 (4.1%) 6 (4.2%) 4 (2.7%) 0.73
Coumadin 12 (3.8%) 6 (4.2%) 4 (2.7%)
Warfarin 1 (0.3%) – –
a Includes n = 131 patients receiving 18.75-mg HPβCD-diclofenac dosage, n = 152 patients receiving 37.5-mg HPβCD-diclofenac dosage, and n = 35
patients receiving 50-mg diclofenac dosage.
b Includes n = 18 patients receiving 15-mg ketorolac dosage and n = 124 patients receiving 30-mg ketorolac dosage.
c From analysis of variance for numerical variables and Cochran-Mantel-Haenszel test for categorical variables.
d Reasons for withdrawal: adverse events (n = 8 [2.5%] HPβCD-diclofenac, n = 2 [1.4%] ketorolac), investigator withdrew patient (n = 1 [0.3%]
HPβCD-diclofenac, n = 1 [0.7%] placebo), lack of efficacy (n = 15 [4.7%] HPβCD-diclofenac, n = 7 [4.9%] ketorolac, n = 11 [7.4%] placebo), lack of
follow-up (n = 6 [1.9%] HPβCD-diclofenac, n = 4 [2.8%] ketorolac, n = 5 [3.4%] placebo), other (n = 2 [0.6%] HPβCD-diclofenac, n = 2 [1.4%]
ketorolac), patient request (n = 3 [0.9%] HPβCD-diclofenac, n = 2 [1.4%] ketorolac, n = 8 [5.4%] placebo), protocol deviation (n = 2 [0.5%]
HPβCD-diclofenac, n = 1 [0.7%] placebo).
e Most common procedures (N5% of subjects in all treatment groups): abdominal hysterectomy, abdominal surgery, bunionectomy/foot bone, inguinal
hernia repair, knee replacement, vaginal hysterectomy, other.
f Other concomitant medications (taken during the study or the 30 days before randomization) with potential anticoagulant effects included acetic acid
derivatives and related substances (HPβCD-diclofenac: n = 39 [12.3%]; ketorolac: n = 13 [9.2%]; placebo: n = 24 [16.2%]) and propionic acid
derivatives (HPβCD-diclofenac: n = 43 [13.5%]; ketorolac: n = 31 [21.8%]; placebo: n = 14 [9.5%])
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olac, and placebo, respectively (Table 3). The only
treatment-related CV AEs occurring in the pooled population
were vascular disorders: flushing (2 patients receiving
HPβCD-diclofenac, 1 receiving placebo), hot flush (1 patient
receiving HPβCD-diclofenac), and thrombophlebitis (2
patients each receiving HPβCD-diclofenac and placebo,
and 1 patient receiving ketorolac). No incidences of angina
pectoris, congestive heart failure, or deep vein thrombosis,
which were uncommon in the study population, were judged
by the study investigator to be treatment-related. Althoughtreatment-related CV AEs were relatively uncommon,
neither active treatment appeared to significantly affect the
risk of experiencing a treatment-related CV AE (HPβCD-
diclofenac RR vs placebo, 1.16 [0.23-5.93]; P = .88;
ketorolac RR vs placebo 0.52 [0.05-5.68]; P = .52).
Table 4 summarizes key demographic features as well as
relevant preexisting conditions in patients who experienced
an SAE during treatment or follow-up. All patients
experiencing an SAE were female and underwent an
orthopedic procedure of the lower extremity (4 total knee
replacements and 1 ankle surgery). Two SAEs, both deep
Table 2 CV adverse events in the study population.
HPβCD-diclofenac (n = 318) Ketorolac (n = 142) Placebo (n = 148)
Patients with ≥1 treatment-emergent:
CV AE, n (%) a 37 (11.6%) 15 (10.6%) 18 (12.2%)
RR vs placebo (95% CI) 0.96 (0.56-1.62); P = .83 0.87 (0.46-1.66); P = .55 –
Cardiac event, n (%) 8 (2.5%) 7 (4.9%) 7 (4.7%)
RR vs placebo (95% CI) 0.53 (0.20-1.44); P = .18 1.04 (0.38-2.90); P = .97 –
Vascular event, n (%) 31 (9.7%) 11 (7.7%) 14 (9.5%)
RR vs placebo (95% CI) 1.03 (0.57-1.88); P = .94 0.82 (0.38-1.74); P = .52 –
Cardiac events by preferred term, n (%)
Angina pectoris 0 (0.0%) 1 (0.7%) 0 (0.0%)
Atrial fibrillation 1 (0.3%) 0 (0.0%) 0 (0.0%)
Bradycardia 1 (0.3%) 0 (0.0%) 1 (0.7%)
Cardiac failure congestive 0 (0.0%) 1 (0.7%) 1 (0.7%)
Palpitations 1 (0.3%) 0 (0.0%) 0 (0.0%)
Supraventricular tachycardia 0 (0.0%) 1 (0.7%) 0 (0.0%)
Tachycardia 5 (1.6%) 5 (3.5%) 6 (4.1%)
Vascular events by preferred term, n (%)
Deep vein thrombosis 3 (0.9%) 0 (0.0%) 0 (0.0%)
Diastolic hypertension 0 (0.0%) 0 (0.0%) 1 (0.7%)
Flushing 3 (0.9%) 1 (0.7%) 1 (0.7%)
Hematoma 1 (0.3%) 0 (0.0%) 0 (0.0%)
Hot flush 1 (0.3%) 0 (0.0%) 0 (0.0%)
Hypertension 2 (0.6%) 3 (2.1%) 2 (1.4%)
Hypotension 12 (3.8%) 4 (2.8%) 6 (4.1%)
Lymphoedema 1 (0.3%) 0 (0.0%) 0 (0.0%)
Orthostatic hypotension 1 (0.3%) 0 (0.0%) 0 (0.0%)
Systolic hypertension 1 (0.3%) 0 (0.0%) 0 (0.0%)
Thrombophlebitis 7 (2.2%) 3 (2.1%) 6 (4.1%)
P values from Cochran-Mantel-Haenszel test comparing treatment and placebo.
a Includes all CV AEs in the study population, including treatment related and non–treatment related; includes patients with 1 or N1 CV AE.
Table 3 Summary of serious CV adverse events, event severity, and treatment-related events.
HPβCD-diclofenac (n = 318) Ketorolac (n = 142) Placebo (n = 148)
Serious CV AEs
Patients with ≥1 serious CV AE, n (%) 3 (0.9%) 1 (0.7%) 1 (0.7%)
RR vs. placebo (95% CI) 1.40 (0.15-13.3); P = .73 1.04 (0.07-16.5); P = .90 –
Serious CV AEs, by preferred term
Cardiac failure congestive 0 (0.0%) 1 (0.7%) 0 (0.0%)
Deep vein thrombosis 3 (0.9%) 0 (0.0%) 0 (0.0%)
Hypotension 0 (0.0%) 0 (0.0%) 1 (0.7%)
CV AE severity
Patients with ≥1 CV AE that was, n (%):
Mild 29 (9.1%) 9 (6.3%) 12 (8.1%)
Moderate 5 (1.6%) 6 (4.2%) 6 (4.1%)
Severe 3 (0.9%) 0 (0.0%) 0 (0.0%)
Relationship to treatment
Patients with ≥1 treatment-related CV AE, n (%) 5 (1.6%) 1 (0.7%) 2 (1.4%)
RR vs placebo (95% CI) 1.16 (0.24-5.93); P = .88 0.52 (0.05-5.68); P = .52 –
Cardiac event, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Vascular event, n (%) 5 (1.6%) 1 (0.7%) 2 (1.4%)
Flushing, n (%) 2 (0.6%) 0 (0.0%) 1 (0.7%)
Hot flush, n (%) 1 (0.3%) 0 (0.0%) 0 (0.0%)
Thrombophlebitis, n (%) 2 (0.6%) 1 (0.7%) 2 (1.4%)
P values from Cochran-Mantel-Haenszel test comparing treatment and placebo.
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Table 4 Summary of patients experiencing a serious CV adverse event during the study period.
Patient ID CV AE Severity Procedure Treatment Suspected
relationship
to treatment?
(Y/N)
Sex Age
(y)
History of
hypertension
or CV
disease?
(Y/N)
Received
medications
for DVT
prophylaxis?
(Y/N)
04-034 Deep vein
thrombosis
Moderate Orthopedic—total
knee replacement
HPβCD-diclofenac,
18.75 mg
N F 73 Y N
05-108 Deep vein
thrombosis
Severe Orthopedic—total
knee replacement
HPβCD-diclofenac,
50 mg
N F 63 Y Y
08-036 Deep vein
thrombosis
Severe Orthopedic—ankle
surgery
HPβCD-diclofenac,
50 mg
N F 37 N N
04-037 Cardiac failure
congestive
Mild Orthopedic—total
knee replacement
Ketorolac,
15 mg
N F 78 Y N
04-042 Hypotension Moderate Orthopedic—total
knee replacement
Placebo N F 62 Y N
DVT = deep vein thrombosis.
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underwent right total knee replacement and occurred 23 days
after first drug dose (20 days after last dose). The second was
in a patient who underwent right ankle surgery and occurred
17 days after first drug dose (16 days after last dose). No
SAEs occurring in the pooled population were treatment
related, and with the exception of 1 patient, all patients
with an SAE were b60 years old and had a history of
hypertension or CV disease. The other patient was a
37-year-old woman who underwent right ankle surgery and
was hospitalized during the follow-up period for multiple
deep thromboses of the right leg. The patient had a history of
hypothyroidism, multiple rhizotomy procedures, stomach
ulcer, morbid obesity, and tobacco use disorder.
Because of existing concerns about serious CV compli-
cations after NSAID use, the timing of CV AEs was also
examined. Most CV AEs occurred either during the
treatment or 5- to 9-day follow-up period (Table 5). A total
of 6 patients experienced ≥1 CV AE during the 30- to
37-day follow-up period (n = 4/318 [1.3%] in the
HPβCD-diclofenac group; n = 2/148 [1.4%] in the placebo
group). None of the CV AEs occurring during the 30- to
37-day follow-up period were suspected of being treatment
related by the investigator.
Examination of CV AEs in the abdominal/pelvic and
orthopedic surgery patient groups showed that CV AE risk
was not significantly increased (or decreased) vs placebo
with HPβCD-diclofenac or the active comparator ketorolac
within either surgical cohort (Supplementary Table 2). CV
AEs were also examined by age (18-50 years, N50-65 years,
N65 years). No significant increase or decrease in CV AE
risk was found with either HPβCD-diclofenac or the active
comparator ketorolac vs placebo in any of the age groups
examined (Supplementary Table 3); however, the number of
patients in each group and in particular the N65 years group
was limited. Finally, there was no significant increase or
decrease in CV AE risk with HPβCD-diclofenac or ketorolacvs placebo for patients receiving 1 to 6 doses (RR:
HPβCD-diclofenac, 0.70 [0.28-1.78]; ketorolac, 0.21
[0.03-1.59]), 7 to 8 doses (RR: HPβCD-diclofenac, 0.90
[0.45-1.83]; ketorolac, 0.79 [0.34-1.85]), or N8 doses (RR:
HPβCD-diclofenac, 2.15 [0.27-16.9]; ketorolac, 3.75
[0.47-30.0]) of study treatment.4. Discussion
The pooled analysis approach used in the present study
allowed for an examination of the CV safety of IV
HPβCD-diclofenac in a diverse yet well-characterized and
closely followed postsurgical population. The 2 trials
included were largely similar in terms of setting, drug
dosages, dosing schedule, and safety analyses. The results of
this analysis suggest that IV HPβCD-diclofenac, when used
to manage acute postoperative pain, did not increase the risk
of CV AEs, as compared to treatment with placebo over the
observation period employed (30- to 37-day follow-up).
Most CV AEs reported were nonserious and either mild or
moderate in severity. Few of the observed CV AEs were
found to be treatment related, including none of the
tachycardia or hypotension events, which were the most
commonly observed CVAEs. This is in line with the fact that
conditions such as tachycardia and hypotension after surgery
are frequently transient and multifactorial. With respect to
CV events of greatest clinical concern, MI or CVA did not
occur in any treatment group, whereas angina pectoris,
congestive heart failure, and deep vein thrombosis were
uncommon and in no instance were treatment related. These
particular CV AEs were likewise found to be uncommon
(and occur at similar rates in treatment and placebo groups)
in a large randomized controlled trial examining CVAE rates
in postoperative patients treated with selective COX-2
inhibitors [24].
Table 5 Timing of CV adverse events.
HPβCD-diclofenac (n = 318) Ketorolac (n = 142) Placebo (n = 148)
Patients with ≥1 treatment-related CV AE during:
Treatment period or 5- to 9-day follow-up period, n (%) 34 (10.7%) 15 (10.6%) 17 (11.5%)
RR vs placebo (95% CI) 0.93 (0.54-1.61); P = .75 0.92 (0.48-1.77); P = .66 –
30- to 37-day follow-up period, n (%) 4 (1.3%) 0 (0.0%) 2 (1.4%)
RR vs placebo (95% CI) 0.93 (0.17, 5.03); P = .96 – –
CV AEs occurring during the follow-up period, n (%)
Cardiac failure congestive 0 (0.0%) 0 (0.0%) 1 (0.7%)
Deep vein thrombosis 2 (0.6%) 0 (0.0%) 0 (0.0%)
Hypertension 0 (0.0%) 0 (0.0%) 1 (0.7%)
Hypotension 1 (0.3%) 0 (0.0%) 0 (0.0%)
Lymphoedema 1 (0.3%) 0 (0.0%) 0 (0.0%)
P values from Cochran-Mantel-Haenszel test comparing treatment and placebo.
CV safety of HPβCD-diclofenac: a pooled analysis of 2 randomized, double-blind, placebo- and active comparator–controlled phase III clinical trials.
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receiving HPβCD-diclofenac (n = 37/318 patients) is in
line with data from a pivotal phase III safety study in a large
postoperative population (n = 971), in which CV AEs were
likewise uncommon and hypotension (6.2% of patients) was
the most common CV AE [18]. Importantly, this large safety
study had fewer exclusion criteria than the studies examined
in the current analysis and, therefore, may be more reflective
of patient populations commonly treated in clinical practice.
Furthermore, another recent study demonstrated no QT
interval prolongation in healthy volunteers receiving IV
HPβCD-diclofenac [25]. The CV AE rates observed with
multiple-dose IV HPβCD-diclofenac as well as the active
comparator in the current study also compare favorably to
those observed with other IV NSAIDs. Tachycardia,
bradycardia, hypertension, and hypotension have previously
been reported to occur in 0% to 6% of patients receiving
postoperative IV ketorolac [26].
There is evidence that advanced age may increase the
likelihood of postoperative CV complications [27]. Although
the present analysis found that HPβCD-diclofenac use was
not associated with a significantly increased CV AE risk over
placebo in patients N65 years old, it is important to note that
the number of patients N65 years old in the pooled study
population was relatively low (72 total patients). This finding
must, therefore, be interpreted cautiously, and larger studies
examining CV risks in an elderly population are warranted.
The present analysis also found no significant increase or
decrease in CV AE risk when patient subgroups based on
number of doses received were examined. Although this
subgroup analysis may be limited by the number of patients
included, it is noteworthy that these results parallel findings
from an open-label safety study, which found no significant
difference in bleeding or renal AE incidences based on
duration of HPβCD-diclofenac dosing [18].
An ongoing concern related to the use of NSAIDs,
including diclofenac, is the elevated risk of serious or
life-threatening complications such as MI, CVA, and atrialfibrillation [7-13]. This has led some regulatory agencies to
recommend that precautions similar to those taken with
selective COX-2 inhibitors (not prescribing for patients with
serious underlying heart conditions; caution when prescrib-
ing for patients with risk factors for heart disease; use of the
lowest dose and for the shortest duration necessary to control
symptoms) be taken with diclofenac [28]. These are
important considerations; however, it must be noted that
studies identifying CV risks associated with NSAID use have
typically focused on use over a longer period than the studies
analyzed in the current report. Meta-analyses have found
increased CV risks with COX-2 inhibitors and nonselective
NSAIDs such as diclofenac by analyzing data from
controlled trials with at least 4 weeks of exposure or
prolonged follow-up periods [7,9]. In addition, a number
of studies identifying an elevated CV risk with long-term
NSAID use involve patient populations that differ considerably
from the surgical populations examined in the present study.
Most notably, these studies frequently include sizeable patient
populations with arthritis, including rheumatoid arthritis [7,13].
Being a chronic systemic inflammatory condition, rheumatoid
arthritis itself is an independent risk factor for CV complications
[8,10,29].
Although concerns related to long-term NSAID use are
clinically important and data suggest that CV risks with
NSAIDs are likely related to duration of exposure [30], the
thresholds for increased CV risks with respect to dosing and
duration of exposure are not well defined. For example, the
results of a case-control study in the UK suggest that the
relative risk of atrial fibrillation is considerably greater with
long-term (N1 year) NSAID use than it is for new
(≤30 days) users, as compared to non-NSAID use [12],
whereas a Danish case-control study suggests that the RR of
atrial fibrillation or flutter is greater for new NSAID users
(≤60 days) than long-term users vs nonusers [11]. Another
study, examining MI risk, found no difference in the risk of
MI with NSAID use for either ≥60 or b60 days vs placebo
[8]. In the postoperative use setting, a study in noncardiac
257Cardiovascular safety of HPβCD-diclofenacsurgery patients found no increase in CV thromboembolic
event risk in patients receiving a regimen of IV and oral
COX-2 inhibitors vs placebo for 10 days [24].
With respect to diclofenac, the results of Andersohn et al
[10] suggest that the risk of serious CV AEs with diclofenac
was elevated in patients with N12 months of ongoing use
(vs b3 months or 3-12 months), whereas the data from the
Danish case-control study [11] suggest an elevated CV risk
in new diclofenac (≤60 days) users. In both studies,
however, a meaningful increase in CV risk was detected
for the shortest exposure groups. It is important to note that
these findings were from case-control studies in which the
duration of NSAID use was based on data for prescriptions
preceding the index date (date of first diagnosis of CV
endpoint of interest), and as a result, the exact duration of
NSAID use may be difficult to ascertain.
The treatment duration examined in the present analysis
does not represent the long-term NSAID use that has been
associated with increased risk of serious CV AEs. Instead,
the exposure period was relatively brief (≤5 days post-
surgery), with safety data collected for a maximum of
37 days posttreatment period. Although the duration of the
follow-up period is a potential limitation of this study in
terms of fully defining potential CV risks, the data indicate
that there was no apparent added CV risk over placebo
during either treatment or follow-up. Similarly, the popula-
tion size examined may represent another limitation. The
included studies were powered to meet primary efficacy end
points and did not include a large proportion of patients with
elevated CV risk. Thus, larger studies, including retrospec-
tive studies making use of large electronic health record
databases, focused on at-risk patients would be warranted to
expand upon these findings. In addition to examining key
groups such as the elderly, such studies could also provide
insight into the potential effects of prior NSAID use by
investigating outcomes in large pools of patients with prior
long-duration NSAID use.
As with many medications, it is important to consider the
risk-benefit balance for NSAID use in any setting. Although
long-term NSAID exposure for the relief of chronic arthritic
pain, for example, may come at a cost of an increased risk of
CV complications, short-term use has not been specifically
shown to demonstrate this risk in the postoperative setting.
Postoperative pain, if untreated, can itself lead to complica-
tions, and recent reviews indicate the benefits of nonselective
NSAIDs such as diclofenac as part of a multimodal
postoperative regimen [1,31,32]. Overall, the results of this
analysis suggest that acute postoperative HPβCD-diclofenac
use did not present any added risk over placebo in the
surgical patient populations examined. Although a larger
trial in a population at greater risk for CV AEs would more
thoroughly assess CV risks, the present findings provide
evidence supportive of the favorable safety profile of
HPβCD-diclofenac in the postoperative setting.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jclinane.2016.01.020.AcknowledgmentsThis study was sponsored by Javelin Pharmaceuticals,
Inc, Cambridge, MA (acquired in 2010 by Hospira, Inc, Lake
Forest, IL) and Hospira, Inc, which was acquired by Pfizer in
September 2015. Hospira, a Pfizer company, provided
support to Boston Strategic Partners, Inc, for editorial
assistance. Scott Paluszkiewicz, PhD, and Fred Peyerl,
PhD, of Boston Strategic Partners, Inc, provided editorial
assistance for this manuscript.References
[1] Macintyre PE, Schug SA, Scott DA, Visser EJ, Walker SM. Acute pain
management: scientific evidence. 3rd ed. Australian and New Zealand
College of Anaesthetists and Faculty of Pain Medicine: Melbourne,
Australia; 2010.
[2] Elia N, Lysakowski C, Tramer MR. Does multimodal analgesia with
acetaminophen, nonsteroidal antiinflammatory drugs, or selective
cyclooxygenase-2 inhibitors and patient-controlled analgesia mor-
phine offer advantages over morphine alone? Meta-analyses of
randomized trials. Anesthesiology 2005;103:1296-304.
[3] Souter AJ, Fredman B, White PF. Controversies in the perioperative
use of nonsterodial antiinflammatory drugs. Anesth Analg 1994;79:
1178-90.
[4] Aubrun F, Marmion F. The elderly patient and postoperative pain
treatment. Best Pract Res Clin Anaesthesiol 2007;21:109-27.
[5] Gurwitz JH. NSAIDs and atrial fibrillation. BMJ 2011;343:d2495.
[6] US FDA - Department of Health and Human Services. Decision
memorandum: analysis and recommendations for agency action:
COX-2 selective and nonselective NSAIDs. Available at http://www.
fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInfor-
mationforPatientsandProviders/ucm106201.pdf. [Accessed September
20, 2013].
[7] Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-
steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;
342:c7086.
[8] Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez
A. Nonsteroidal antiinflammatory drugs and the risk of myocardial
infarction in the general population. Circulation 2004;109:3000-6.
[9] Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N,
Emberson J, et al. Vascular and upper gastrointestinal eff ects of non-
steroidal anti-infl ammatory drugs: meta-analyses of individual
participant data from randomised trials. Lancet 2013;382:769-79.
[10] Andersohn F, Suissa S, Garbe E. Use of first- and second-generation
cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and
risk of acute myocardial infarction. Circulation 2006;113:1950-7.
[11] Schmidt M, Christiansen CF, Mehnert F, Rothman KJ. Non-steroidal
anti-inflammatory drug use and risk of atrial fibrillation or flutter:
population based case-control study. BMJ 2011;343:d3450.
[12] De Caterina R, Ruigomez A, Garcia Rodriguez LA. Long-term use of
anti-inflammatory drugs and risk of atrial fibrillation. Arch Intern Med
2010;170:1450-5.
[13] Zhang J, Ding EI, Song Y. Adverse effects of cyclooxygenase 2
inhibitors on renal and arrhythmia events: meta-analysis of random-
ized trials. JAMA 2006;296:1619-32.
[14] Leeson RM, Harrison S, Ernst CC, et al. Dyloject, a novel injectable
diclofenac formulation, offers greater safety and efficacy than
Voltarol for postoperative dental pain. Reg Anesth Pain Med 2007;
32:303-10.
258 T.J. Gan et al.[15] Colucci RD, Wright C, Mermelstein FH, Gawarecki DG, Carr DB.
Dyloject®, a novel injectable diclofenac solubilised with cyclodextrin:
reduced incidence of thrombophlebitis compared to injectable
diclofenac solubilised with polyethylene glycol and benzyl alcohol.
Acute Pain 2009;11:15-21.
[16] Gan TJ, Daniels SE, Singla N, Hamilton DA, Carr DB. A novel
injectable formulation of diclofenac compared with intravenous
ketorolac or placebo for acute moderate-to-severe pain after abdominal
or pelvic surgery: a multicenter, double-blind, randomized, multiple-
dose study. Anesth Analg 2012;115:1212-20.
[17] Daniels S, Melson T, Hamilton DA, Lang E, Carr DB. Analgesic
efficacy and safety of a novel injectable formulation of diclofenac
compared with intravenous ketorolac and placebo after orthopedic
surgery: a multicenter, randomized, double-blinded, multiple-dose
trial. Clin J Pain 2013;29:655-63.
[18] Chelly JE, Singla SK, Melson TI, Lacouture PG, Paadre S, Carr
DB. Safety of a novel parenteral formulation of diclofenac after
major orthopedic or abdominal/pelvic surgery in a population
including anticoagulated, elderly or renally insufficient patients: an
open-label, multiday, repeated dose clinical trial. Pain Med 2013;
14:749-61.
[19] Mermelstein F, Hamilton DA, Wright C, Lacouture PG, Ramaiya A,
DB C.. Single-dose and multiple-dose pharmacokinetics and dose
proportionality of intravenous and intramuscular HPβCD-diclofenac
(Dyloject) compared with other diclofenac formulations. Pharmaco-
therapy 2013;33:1012-21.
[20] Christensen K, Daniels S, Bandy D, et al. A double-blind placebo-
controlled comparison of a novel formulation of intravenous
diclofenac and ketorolac for postoperative third molar extraction
pain. Anesth Prog 2011;58:73-81.
[21] Bedford Laboratories. Ketorolac tromethamine injection, solution
product label. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?
setid=4f49a276-a199-4f98-afaf-10a3eca91923. [Accessed October
22, 2013].
[22] Medical Dictionary for Regulatory Activities (MedDRA), version 9.1.
Reston, VA: MedDRA MSSO; 2006.[23] Cancer Therapy Evaluation Program. Common terminology criteria
for adverse events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31,
2003; 2003[http://ctep.cancer.gov].
[24] Nussmeier NA, Whelton AA, Brown MT, et al. Safety and efficacy of
the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after
noncardiac surgery. Anesthesiology 2006;104:518-26.
[25] Carr DB, McDonnell Moorehead T, Bouchard A, et al. Effects of
injectable HPβCD-diclofenac on the human delayed rectifier potas-
sium channel current in vitro and on proarrhythmic QTc in vivo. Clin
Ther 2013;35:646-58.
[26] O'Hara DA, Fanciullo G, Hubbard L, et al. Evaluation of the safety
and efficacy of ketorolac versus morphine by patient-controlled
analgesia for postoperative pain. Pharmacotherapy 1997;17:891-9.
[27] Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL.
Frequency of myocardial infarction, pulmonary embolism, deep
venous thrombosis, and death following primary hip or knee
arthroplasty. Anesthesiology 2002;96:1140-6.
[28] European Medicines Agency. PRAC recommends the same cardio-
vascular precautions for diclofenac as for selective COX-2 inhibitors.
Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/
news_and_events/news/2013/06/news_detail_001816.jsp&mid=
WC0b01ac058004d5c1. [Accessed September 26, 2013].
[29] Chung WS, Lin CL, Peng CL, et al. Rheumatoid arthritis and risk of
acute myocardial infarction—a nationwide retrospective cohort study.
Int J Cardiol 2013;168:4750-4.
[30] Grosser T, Fries S, FitzGerald GA. Biological basis for the
cardiovascular consequences of COX-2 inhibition: therapeutic challenges
and opportunities. J Clin Invest 2006;116:4-15.
[31] American Society of Anesthesiologists Task Force on Acute Pain
Management. Practice guidelines for acute pain management in the
perioperative setting: an updated report by the American Society of
Anesthesiologists Task Force on Acute PainManagement. Anesthesiology
2012;116:248-73.
[32] Krenzischek DA, Dunwoody CJ, Polomano RC, Rathmell JP.
Pharmacotherapy for acute pain: implications for practice. J Perianesth
Nurs 2008;23:S28-42.
